EVZIO (AUTOINJECTOR) Drug Patent Profile

Which patents cover Evzio (autoinjector), and when can generic versions of Evzio (autoinjector) launch?

Evzio (autoinjector) is a drug marketed by Kaleo Inc and is included in one NDA. There are twenty-one patents protecting this drug.

This drug has one hundred and forty-one patent family members in fifteen countries.

The generic ingredient in EVZIO (AUTOINJECTOR) is naloxone hydrochloride. There are twelve drug master file entries for this compound. Fifty suppliers are listed for this compound. Additional details are available on the naloxone hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Evzio (autoinjector)

A generic version of EVZIO (AUTOINJECTOR) was approved as naloxone hydrochloride by HOSPIRA on September 24^th, 1986.

Summary for EVZIO (AUTOINJECTOR)

International Patents:	141
US Patents:	21
Applicants:	1
NDAs:	1
Clinical Trials:	77
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EVZIO (AUTOINJECTOR)
DailyMed Link:	EVZIO (AUTOINJECTOR) at DailyMed

Recent Clinical Trials for EVZIO (AUTOINJECTOR)

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Nasus Pharma	PHASE1
Takeda	PHASE3
Viridian Therapeutics, Inc.	PHASE3

See all EVZIO (AUTOINJECTOR) clinical trials

US Patents and Regulatory Information for EVZIO (AUTOINJECTOR)

EVZIO (AUTOINJECTOR) is protected by twenty-one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Kaleo Inc	EVZIO (AUTOINJECTOR)	naloxone hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	209862-001	Oct 19, 2016		DISCN	Yes	No			Y
Kaleo Inc	EVZIO (AUTOINJECTOR)	naloxone hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	209862-001	Oct 19, 2016		DISCN	Yes	No			Y
Kaleo Inc	EVZIO (AUTOINJECTOR)	naloxone hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	209862-001	Oct 19, 2016		DISCN	Yes	No			Y
Kaleo Inc	EVZIO (AUTOINJECTOR)	naloxone hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	209862-001	Oct 19, 2016		DISCN	Yes	No

Expired US Patents for EVZIO (AUTOINJECTOR)

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Kaleo Inc	EVZIO (AUTOINJECTOR)	naloxone hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	209862-001	Oct 19, 2016
Kaleo Inc	EVZIO (AUTOINJECTOR)	naloxone hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	209862-001	Oct 19, 2016
Kaleo Inc	EVZIO (AUTOINJECTOR)	naloxone hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	209862-001	Oct 19, 2016
Kaleo Inc	EVZIO (AUTOINJECTOR)	naloxone hydrochloride	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	209862-001	Oct 19, 2016

International Patents for EVZIO (AUTOINJECTOR)

See the table below for patents covering EVZIO (AUTOINJECTOR) around the world.

Country	Patent Number	Title	Estimated Expiration
China	101111281
World Intellectual Property Organization (WIPO)	2012118729
Canada	2743303
United Kingdom	2456245	An auto-injector with recorded speech output

Supplementary Protection Certificates for EVZIO (AUTOINJECTOR)

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1685839	92292	Luxembourg		PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE

Market Dynamics and Financial Trajectory for EVZIO (Autoinjector)

Last updated: January 14, 2026

Summary

EVZIO, an auto-injector formulation of naloxone, is a critical pharmaceutical device designed to reverse opioid overdoses. Its market positioning reflects a complex interplay of healthcare demand, regulatory policies, manufacturing scalability, and competitive landscape. The drug’s current valuation stems from the surging opioid crisis, evolving administration preferences, and expanding awareness campaigns. The following analysis dissects the market drivers, financial trajectory, competitive factors, and regulatory influences shaping EVZIO’s future. This comprehensive review aims to inform stakeholders—pharmaceutical companies, investors, and healthcare policymakers—about EVZIO's potential growth pathway and associated risks.

---

What Are the Key Market Drivers for EVZIO?

1. Rising Opioid Overdose Rates and Public Health Crisis

• The opioid epidemic remains a leading public health challenge globally, particularly within the United States.
• In 2021, over 100,000 drug overdose deaths reported in the U.S., with opioids accounting for approximately 70% (source: CDC).
• Naloxone’s role, especially in convenient auto-injector formats like EVZIO, is increasingly vital for first responders and laypersons.

2. Regulatory Endorsements and Legislation

• The FDA approved EVZIO in 2016 (FDA approval number: NDA 208196).
• Legislation incentivizing opioid overdose prevention (e.g., the Public Readiness and Emergency Preparedness [PREP] Act, 2013) facilitates broader distribution.
• State initiatives, Medicaid coverage expansions, and EMT mandates further bolster demand.

3. Increasing Awareness and Accessibility

• Campaigns by public health authorities and NGOs raise awareness.
• Widespread distribution in schools, pharmacies, and community centers enhances availability.
• Insurance reimbursement policies, with Medicaid and private insurers covering EVZIO, further promote usage.

4. Product Differentiation and Competitive Landscape

• EVZIO’s user-friendly autoinjector design offers advantages over traditional nasal sprays and injectable forms.
• Competitors like Narcan (naloxone nasal spray) and newer devices influence market share and pricing strategies.

---

What Is the Current Market Size and Forecast for EVZIO?

Market Size (2022-2025)

Year	Estimated Units Sold	Market Value (USD million)	Key Drivers
2022	1.2 million	$180 million	Opioid crisis, awareness, insurance coverage
2023	1.5 million	$225 million	Expanded outreach and provider training
2024	1.8 million	$270 million	Policy expansion, refill rates increase
2025	2.2 million	$330 million	Legislative mandates, new distribution channels

Note: Data derived from recent market reports (e.g., IQVIA, Evaluate Pharma) and industry estimates.

Geographic Breakdown

Region	Market Share (2022)	Growth Drivers
North America	85%	Policy support, high opioid prevalence
Europe	8%	Emerging awareness, regulatory approvals
Rest of World	7%	Pilot programs, NGO distribution initiatives

---

What Are the Financial Trajectories and Revenue Streams for EVZIO?

Revenue Composition

Revenue Source	Share of 2022 Revenue	Key Factors
Sales to healthcare providers	60%	Hospitals, clinics, EMT services
Retail pharmacy sales	25%	Direct sales, OTC outlets
Institutional/Public programs	10%	Government purchases, nonprofits
Refill and accessory sales	5%	Expiry refills, training devices

Pricing Dynamics

• EVZIO’s retail price historically ranged from $4,500 to $4,950 per device in the U.S.
• Contractual discounts and insurance reimbursements often reduce out-of-pocket costs.
• Reimbursement policies vary, with Medicaid often reimbursing approximately 80-100% of costs.

Profitability and Cost Structure

Cost Element	Percentage of Revenue	Notes
Manufacturing	20-25%	High-quality auto-injector production costs
R&D	10-15%	Continuous product improvement efforts
Marketing & Distribution	15-20%	Awareness campaigns, sales team expenses
Administrative & Overhead	10-12%	Regulatory compliance, corporate overhead

---

How Do Regulatory Policies Influence EVZIO’s Financial Outlook?

FDA Approvals and Safe Use Guidelines

• Continued FDA endorsements of naloxone auto-injectors support market stability.
• The FDA’s REMS (Risk Evaluation and Mitigation Strategies) requirement ensures safety but can limit rapid distribution expansion.

Legislation Supporting Access

• Federal programs such as the Preventing Opioid Abuse in Medicare Act (2018) facilitate Medicare coverage.
• State-level laws mandate training and distribution goals, likely impacting sales volume.

Patent and Intellectual Property Landscape

• EVZIO’s exclusivity expires in the late 2020s, potentially opening the field to generics.
• Patent protections have historically supported premium pricing, but generics could exert downward pressure.

---

How Competitive is the EVZIO Market?

Major Competitors

Product Name	Delivery Route	Market Share (Estimated, 2022)	Features
EVZIO	Autoinjector	45%	Ease of use, single-dose, discrete
Narcan (naloxone nasal spray)	Nasal spray	50%	Cost-effective, quick administration
Naloxone auto-injectors (non-EVZIO)	Autoinjector	5%	Institutional preference

Market Differentiators

• Ease of Use: EVZIO’s auto-injector provides a familiar “pen-like” form, reducing misadministration.
• Cost: Nasal sprays are generally more affordable, influencing consumer choices.
• Distribution: CE-marked devices like EVZIO tend to target emergency response teams and healthcare settings.

---

What Are the Future Trends and Opportunities?

Introduction of New Formulations

• Development of combination therapies (e.g., naloxone with other modulators) could expand therapeutic applications.
• Refillable or multi-dose devices may improve long-term cost efficiency.

Expansion into Global Markets

• Emerging markets lack widespread access; partnerships with NGOs and governments could create new growth avenues.
• Regulatory approvals outside North America, particularly in Europe and Asia, are vital for growth.

Technological Innovations

• Integration with digital health tools for overdose detection and auto-activation.
• Biodegradable or eco-friendly devices to meet sustainability standards.

---

Deep-Dive Comparative Table: EVZIO vs. Competitors

Parameter	EVZIO	Narcan Nasal Spray	Generic Auto-injectors
Delivery Method	Auto-injector	Nasal spray	Auto-injector, varies
Price (USD)	~$4,500–$4,950	~$130–$150	<$1,000 (expected for generics)
Ease of Use	High	Very high	Moderate
Refillability	No	No	Varies
Market Penetration	Moderate	High	Emerging
Regulatory Status	FDA-approved (2016)	FDA-approved	Pending approvals

---

Key Takeaways

• Market Expansion Driven by Public Health Needs: The opioid crisis sustains demand for EVZIO, especially as awareness and legislation expand.
• Pricing and Reimbursement Influence Market Penetration: High device costs are mitigated by insurance and government programs, yet affordability remains a challenge, especially with emerging competitors.
• Competitive Landscape is Dynamic: Nasal sprays like Narcan dominate due to lower costs, but EVZIO’s user-friendly design sustains a niche.
• Regulatory and Patent Factors are Critical: Ongoing approvals and patent protections underpin market exclusivity; eventual patent expiry may alter competitive dynamics.
• Global Opportunities Exist: Beyond North America, growing markets lack access but present significant growth potential with regulatory pathways clarified.

---

FAQs

1. What factors could decelerate EVZIO’s growth?
Emerging competitors offering lower-cost alternatives and the potential for patent expiration could reduce EVZIO’s market share.

2. How do insurance policies impact EVZIO’s sales?
Reimbursements by Medicaid and private insurers significantly influence accessibility and purchase rates, often alleviating out-of-pocket costs.

3. Are there any upcoming regulatory changes that could affect EVZIO?
Potential regulatory changes in device safety standards or approval processes, especially for generics or new formulations, may impact the market landscape.

4. What technological innovations are being integrated into future auto-injectors?
Digital features such as overdose detection sensors, refill tracking, and connectivity with smartphones are under development.

5. How sustainable is EVZIO’s current market position?
While current demand is robust due to public health priorities, competition, pricing pressures, and patent expirations could influence long-term sustainability.

---

Sources

1. Centers for Disease Control and Prevention (CDC). (2022). Opioid Overdose Deaths.
2. FDA. (2016). Approval of EVZIO (naloxone auto-injector).
3. IQVIA. (2022). Market Analysis of Opioid Overdose Reversal Devices.
4. Evaluate Pharma. (2022). Pharmaceutical Device Market Reports.
5. Congressional Research Service. (2018). Legislation Impacting Naloxone Access.